Worth Watching Stocks on the Run: Microsoft Corporation (NASDAQ:MSFT), Cousins Properties Inc (NYSE:CUZ), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

On Tuesday, Shares of Microsoft Corporation (NASDAQ:MSFT), subtract -0.31% and closed at $57.24 in the last trading session. The last trading range of the stock ranges between $56.97 and $57.60. Microsoft Corporation, a technology company, develops, licenses, and supports software products, services, and devices worldwide. The company’s Productivity and Business Processes segment offers Office 365 commercial products and services for businesses, counting Office, Exchange, SharePoint, and Skype, in addition to related Client Access Licenses (CALs); Office 365 consumer services, such as Skype, Outlook.com, and OneDrive; and Dynamics business solutions, counting financial administration, customer relationship administration, supply chain administration, and analytics applications for small and mid-size businesses, large organizations, and divisions of various enterprises. Its Intelligent Cloud segment licenses server products and cloud services, such as SQL Server, Windows Server, Visual Studio, System Center, and related CALs, in addition to Azure, a cloud platform with computing, networking, storage, database, and administration services; and enterprise services, such as Premier Support and Microsoft Consulting services that assist in developing, deploying, and managing Microsoft server and desktop solutions, in addition to provide training and certification to developers and IT professionals on Microsoft products. The company’s More Personal Computing segment comprises Windows OEM, volume, and other non-volume licensing of the Windows operating system, in addition to patent licensing, Windows Embedded, MSN display advertising, and Windows Phone licensing system; devices, counting Microsoft Surface, phones, and PC accessories; and search advertising, counting Bing and Bing Ads.

Cousins Properties Inc (NYSE:CUZ), jumped 2.46% and closed at $10.41 in the last trading session. The last trading range of the stock ranges between $10.12 and $10.49. The company’s Market capitalization is $2.18 Billion with the total Outstanding Shares of 220.50 million. S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:

S&P SmallCap 600 constituent Cousins Properties Inc. (CUZ) will replace Community Health Systems, Inc. (CYH) in the S&P MidCap 400, Community Health Systems will replace Cousins Properties, and Ollie’s Bargain Outlet Holdings, Inc. (OLLI) will replace Parkway Properties Inc. (PKY) in the S&P SmallCap 600 after the close on Wednesday, October 5. Cousin Properties is acquiring Parkway Properties in a deal expected to be accomplished soon pending final conditions. Cousins Properties will have GICS change to Office REITs following the merger. Community Health Systems is ranked near the bottom of the S&P MidCap 400 and has a market capitalization more representative of the small-cap market space.

Parkway Inc (PKY) will replace VOXX International Corp (VOXX) in the S&P SmallCap 600 after the close on Friday, October 7. Newly added S&P MidCap 400 constituent Cousins Properties Inc. is spinning off Parkway Inc. in a transaction that is expected to be accomplished by Thursday, October 6 pending final conditions. Cousins Properties will remain in the S&P MidCap 400 post spin off. Voxx International is ranked near the bottom of the S&P SmallCap 600 and is no longer representative of the small-cap market space.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), gained 8.02% and closed at $3.50 in the last trading session. The last trading range of the stock ranges between $3.24 and $3.75. During the 52-week trading session the minimum price at which share price traded, registered at $1.42 and reached to max level of $4.49. Aurinia Pharmaceuticals Inc. (AUPH) (AUP.TO) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, recently declared that in addition to voclosporin (23.7 mg BID) achieving its primary endpoint of Complete Remission (CR) at 24 weeks, both doses of voclosporin when added to the current standard of care of Mycophenolate Mofetil (MMF) and a forced oral corticosteroid taper have met all 24-week pre-specified secondary endpoints vs the control group. These pre-specified endpoints include: Partial Remission (PR), which is measured by a ≥50% reduction in UPCR with no concomitant use of rescue medication; time to CR and PR; reduction in Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in UPCR over the 24-week treatment period.

The AURA-LV study remains ongoing to its 48-week endpoint upon which similar and additional secondary analysis will be analysed and presented early next year.

“We are thrilled by the results of the AURA study and voclosporin’s potential to shift the treatment paradigm for active lupus nephritis,” said Charles Rowland, CEO of Aurinia. “The ability to get more patients into remission and in a shorter period time than the current standard of care can have a noteworthyimpact on the long-term outcomes for these patients.”

Leave a Reply

Your email address will not be published. Required fields are marked *